You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,988,961


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,988,961
Title:Gut commensal bacterium and methods of using the same
Abstract: The invention provides gut commensal bacteria that have been modified to express one or more biologically active polypeptides or protiens, the bacteria includes a promoter, such as a xylanase promoter, which is induced in response to the presence of xylan in the diet and which regulates the expression of the biologically active polypeptide or protien.
Inventor(s): Farrar; Mark (Leeds, GB), Carding; Simon (Leeds, GB)
Assignee: Plant Bioscience Limited (GB)
Application Number:11/814,739
Patent Claims:1. A recombinant Bacteroides ovatus gut commensal bacterium deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB) Accession No. 41521, 41522 or 41523 wherein the bacterium comprises a xylanase promoter that regulates expression of a polypeptide or protein and wherein the promoter is induced in the presence of dietary xylan.

2. The bacterium of claim 1, wherein the bacterium is non-pathogenic to man.

3. The bacterium of claim 1, wherein the polypeptide or protein is selected from the group consisting of insulin, growth hormone, prolactin, calcitonin, luteinizing hormone, parathyroid hormone, somatostatin, thyroid stimulating hormone, vaccines, antigens, vasoactive intestinal polypeptide, trefoil factors, cell and tissue repair factors, transforming growth factor .beta., keratinocyte growth factor, a structural group 1 cytokine adopting an antiparallel 4.alpha. helical bundle selected from the group consisting of IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-12, IL-13, GM-CSF, M-CSF, SCF, IFN-.gamma., EPO, G-CSF, LIF, OSM, CNTF, GH, PRL or IFN.alpha./.beta., a structural group 2 cytokine selected from the group consisting of TNF.alpha., TNF.beta., CD40, CD27 or FAS ligands, IL-1 family of cytokines, fibroblast growth factor family, platelet derived growth factors, transforming growth factor .beta. and nerve growth factors, a structural group 3 cytokine, epidermal growth factor family of cytokines, chemokines, insulin related cytokines, and a structural group 4 cytokine selected from the group consisting of EGF, immunoglobulin-like and kringle domains.

4. The bacterium of claim 1, wherein the bacterium of NCIMB Accession No. 41521, 41522 or 41523 expresses a plurality of polypeptides or proteins.

5. A pharmaceutical composition comprising: (a) a recombinant Bacteroides ovatus gut commensal bacterium deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB) Accession No. 41521, 41522 or 41523 wherein the bacterium comprises a xylanase promoter that regulates expression of a polypeptide or protein and wherein the promoter is induced in the presence of dietary xylan; and (b) a pharmaceutically acceptable carrier, diluent or excipient.

6. A method of treating chronic inflammatory bowel disease comprising administering to a subject in need thereof an effective amount of a recombinant Bacteroides ovatus gut commensal bacterium deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB) Accession No. 41521, 41522 or 41523 wherein the bacterium comprises a xylanase promoter that regulates expression of a polypeptide or protein and wherein the promoter is induced in the presence of dietary xylan.

7. A method of treating chronic inflammation of the gut comprising administering to a subject in need thereof an effective amount of a recombinant Bacteroides ovatus gut commensal bacterium deposited at the National Collection of Industrial, Food and Marine Bacteria (NCIMB) Accession No. 41521, 41522 or 41523 wherein the bacterium comprises a xylanase promoter that regulates expression of a polypetide or protein and wherein the promoter is induced in the presence of dietary xylan.

8. The bacterium of claim 1, wherein polypeptide or protein is obtained from a eukaryotic, prokaryotic or viral source.

9. The recombinant Bacteroides ovatus gut commensal bacterium of claim 1, wherein the bacterium further comprises a Bacteroides fragilis endotoxin secretion signal sequence to mediate secretion of the Polypeptide or protein.

10. The pharmaceutical composition of claim 5, wherein the bacterium further comprises a Bacteroides fragilis endotoxin secretion signal sequence to mediate secretion of the polypeptide or protein.

11. The method of claim 6, wherein the bacterium further comprises a Bacteroides fragilis endotoxin secretion signal sequence to mediate secretion of the polypeptide or protein.

12. The method of claim 7, wherein the bacterium further comprises a Bacteroides fragilis endotoxin secretion signal sequence to mediate secretion of the polypeptide or protein.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.